LC
TERN

Lindbrook Capital’s Terns Pharmaceuticals TERN Stock Holding History

Lindbrook Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63
Closed -$525 – 2906
2024
Q3 		$525 Buy
63
+1
+2% +$8 ﹤0.01% 2651
2024
Q2 		$422 Buy
+62
New +$376 ﹤0.01% 2660
2023
Q3 		– Sell
-24
Closed -$210 – 2824
2023
Q2 		$210 Sell
24
-106
-82% -$1.24K ﹤0.01% 2647
2023
Q1 		$1.54K Buy
+130
New +$1.24K ﹤0.01% 2347

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lindbrook Capital's TERN Position: Q4 2024 in Review

Lindbrook Capital sold out of Terns Pharmaceuticals (TERN) in Q4 2024, closing a stake of 63 shares — an estimated $525 sold.

Lindbrook Capital first reported a position in TERN in Q1 2023 and held it in 4 quarters. The position peaked at $1.54K in Q1 2023. 157 funds tracked by Wall St. Rank hold TERN as of Q4 2024.

  • Lindbrook Capital reported no remaining Terns Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 63 Terns Pharmaceuticals shares in Q4 2024, an estimated $525.
  • Lindbrook Capital first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Lindbrook Capital's Terns Pharmaceuticals position peaked at $1.54K in Q1 2023.
  • 157 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.